Clinical trials: SARS-CoV-2 Infection
Covid19
The Nanowear Wearable Covid-19 Observational and Analysis Trend
The NanoCOAT study is a multi-center, prospective, non-randomized, feasibility, observational, non-significant risk study. The NanoCOAT study will enroll a minimum of 10 and a maximum of 100 subjects in a potential for a…
- Trial name
- NanoCOAT (NCT04717024)
- Testing
- Observational Study - no intervention
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nanowear Inc.
COVID-19, Coronavirus Infection
Relative Bioavailability Study of CX2101A for the Treatment of COVID-19
The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and…
- Trial name
- NCT06864182
- Testing
- CX2101A tablet, CX2101A enteric-coated tablet
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Heronova Pharmaceuticals
COVID-19 Respiratory Infection, Viral Pneumonia
Study of the Use of the Drug Ingaron in Patients With COVID-19
Interferon gamma is a powerful endogenous regulatory cytokine that activates the antiviral immune response, while it also has its own antiviral activity.
- Trial name
- NCT05386459
- Testing
- Interferon Gamma
- Where
- Russia
- Volunteers
- 36 people
- Sponsor
- SPP Pharmaclon Ltd.
Post Acute COVID-19 Syndrome, Long COVID
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
This is a randomized (1:1) , placebo-controlled phase II study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms.
- Conditions
- Post Acute COVID-19 Syndrome, Long COVID, COVID-19 Respiratory Infection
- Trial name
- NCT04949386
- Testing
- S-1226 (8%)
- Volunteers
- 48 people
- Sponsor
- SolAeroMed Inc.
SARS-CoV-2
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT)…
- Trial name
- NCT04860297
- Testing
- mRNA-1273
- Where
- 15 sites in United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study).
- Conditions
- COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation
- Trial name
- NCT04788459
- Testing
- COVID-eVax, Cliniporator® and EPSGun
- Where
- 4 sites in Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Takis
ARDS, Human, Covid-19
Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19
This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days…
- Trial name
- NCT04456361
- Testing
- Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords
- Where
- Mexico
- Volunteers
- 9 people
- Sponsor
- Instituto de Medicina Regenerativa
COVID-19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
The purpose of this study is to assess the immunogenicity and safety of MVC- COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05198596
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Thailand
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with ARDS due to coronavirus infection 2019 (COVID-19).
- Trial name
- NCT04366830
- Testing
- Remestemcel-L
- Where
- United States
- Sponsor
- Mesoblast International Sàrl
Covid19, SARS-CoV Infection
Proxalutamide Treatment for COVID-19 Female Outpatients
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Trial name
- NCT04853134
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
Covid19
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
Indication : Treatment of Subject with COVID-19 infection Phase : Phase I Duration of Study : 12 day Sample size : at least 15 subjects Methodology : Classical 3+3 design Investigational Product : MPT0B640, 15, 30, 60, 80 and…
- Trial name
- NCT04526717
- Testing
- MPT0B640
- Sponsor
- J Ints Bio
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
This study is a multi-center and open design, phase Ⅳ clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development Co., Ltd.The purpose of this study is to evaluate the safety…
- Trial name
- NCT04911790
- Testing
- Experimental Group
- Where
- China
- Volunteers
- 131,650 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Cardiovascular Diseases
Registry for a Cardiovascular Patient Who COVID-19 Infection in Qatar and Gulf
The novel coronavirus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID -19), is highly contagious in the community and has resulted in a global pandemic.
- Trial name
- NCT04430374
- Testing
- No interverntion
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Mild to Moderate COVID-19
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
The study is a multicenter, randomized, double-blind, placebo-controlled efficacy, safety Phase III clinical trial designed to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19.
- Trial name
- NCT06197217
- Testing
- WPV01
- Where
- China
- Volunteers
- 1,350 people
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19
This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901.
- Trial name
- NCT04487210
- Testing
- MVC-COV1901
- Where
- Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
SARS-CoV2 Infection, COVID-19
COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV-2 rapid antigen over the counter clinical performance evaluation
- Trial name
- NCT05584176
- Testing
- iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
- Where
- 4 sites in United States
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- MP Biomedicals, LLC
COVID-19
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05758519
- Testing
- QLS1128
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Bioequivalence
The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride and a single dose of Test product containing 200 mg umifenovir hydrochloride monohydrate…
- Trial name
- Umifenovir (NCT04476719)
- Testing
- ATAFENOVIR 200 MG KAPSUL, ARBIDOL 100 MG KAPSUL
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
COVID-19 Vaccine
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05216601
- Testing
- MVC-COV1901, MVC-COV1901(Beta)-15, MVC-COV1901(Beta)-25
- Where
- 2 sites in Taiwan
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.